Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Inc

For Immediate Release
Chicago, IL – December 22, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Walmart Inc. WMT, Wells Fargo & Co. WFC, Thermo Fisher Scientific Inc. TMO, Seneca Foods Corp. SENEA and NetSol Technologies, Inc. NTWK.
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Walmart, Wells Fargo & Thermo Fisher Scientific
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc., Wells Fargo & Co. and Thermo Fisher Scientific Inc., as well as two micro-cap stocks Seneca Foods Corp. and NetSol Technologies, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Are the Markets Setting Up for a Santa Claus Rally?
Today's Featured Research Reports
Walmart's shares have outperformed the Zacks Retail - Supermarkets industry over the past six months (+21.3% vs. +19.9%). The company's performance reflects strong execution across its omnichannel model, with robust store-led fulfillment, solid e-commerce growth and sustained market share gains.
Third-quarter fiscal 2026 results highlight robust comparable sales, broad-based traffic growth and rapidly expanding higher-margin businesses such as advertising and membership, which represent a meaningful share of operating income. Faster delivery speeds, improved inventory availability and marketplace expansion continue to support e-commerce growth. Management's raised fiscal 2026 view underscores confidence in sustaining growth.
However, margin expansion remains constrained by elevated operating costs and tariff risks. Currency volatility, intense competition and an ongoing mix shift toward lower-margin essentials amid macroeconomic uncertainty are also concerns.
(You can read the full research report on Walmart here >>>)
Shares of Wells Fargo have outperformed the Zacks Financial - Investment Bank industry over the past six months (+23.7% vs. +22.3%). The company's earnings surpassed the estimates in each of the trailing four quarters. The Federal Reserve's June 2025 removal of the $1.95 trillion asset cap allows growth in deposits, loans, and fee-based services.
The bank also gains room to scale fee-based businesses like payment services and asset management, enhancing its revenue mix. After clearing the 2025 Fed stress test, Wells Fargo raised its dividend, backed by strong liquidity and capital position. Also, strategic investments in talent and technology support long-term growth.
Yet, despite the recent Fed rate cuts, NII recovery may remain slow, pressuring near-term revenue growth. The mortgage banking income remains weak amid ongoing mortgage rate volatility. Also, rising expense base may weigh on its profitability.
(You can read the full research report on Wells Fargo here >>>)
Thermo Fisher Scientific's shares have outperformed the Zacks Medical - Instruments industry over the past six months (+43.5% vs. +16.9%). The company continues to strengthen its foundation by consistently advancing its growth strategy. The company's latest round of innovations supports scientific breakthroughs, advances precision medicine and greater lab productivity for customers.
Thermo Fisher is embedding OpenAI's capabilities into its products and services to make an even bigger impact for customers and enhance productivity. Strategic acquisitions, such as the newly added Solventum's Purification and Filtration Business, further enhance its offerings.
The Zacks' model forecasts a 5.1% CAGR growth in the company's revenues through 2025-2027. Meanwhile, a highly leveraged balance sheet poses liquidity concerns. Shifting U.S. policies have weighed on the academic and government end-market clients, affecting its sales. Currency woes add to the worry.
(You can read the full research report on Thermo Fisher Scientific here >>>)
Shares of Seneca Foods have outperformed the Zacks Food - Miscellaneous industry over the past six months (+26.2% vs. -7.8%). This microcap company with market capitalization of $771.74 million benefits from resilient global demand for affordable, shelf-stable foods, with first-half fiscal 2026 sales up 3.7% and strong volume growth led by canned and frozen vegetables, which remain more than 82.5% of sales.
Improved harvest yields, pack efficiency and structural cost controls are supporting margin normalization, as high-cost inventory rolls off. Deleveraging, lower interest expense and ample liquidity have strengthened the balance sheet, while the Green Giant shelf-stable acquisition enhances branded scale and mix.
Yet, margin gains are heavily influenced by LIFO credits, masking underlying FIFO cost pressure and earnings volatility. Elevated inventories increase working-capital risk and variable-rate debt maintains sensitivity to rates. Valuation is compelling, offering upside if normalized margins and cash flow durability are sustained.
(You can read the full research report on Seneca Foods here >>>)
NetSol Technologies' shares have outperformed the Zacks Computer - Software industry over the past six months (+7.1% vs. -2.1%). This microcap company with market capitalization of $36.57 million operates in a large, underpenetrated global asset finance and leasing software market undergoing ongoing digital transformation. Its AI-enabled, modular Transcend Platform is seeing growing adoption among OEMs, captives, and financial institutions.
NetSol Technologies' transition to a SaaS and cloud-first model is improving predictability. Investments in AI, including Check AI and Transcend AI Labs, enhance product differentiation and scalability, while partnerships across China and Southeast Asia reinforce regional positioning.
Balancing the opportunity are ongoing risks, including the structural decline of high-margin license revenue, margin pressure from rising SG&A and FX volatility, and earnings sensitivity to currency movements. High customer concentration, uneven services growth, and working capital pressure continue to weigh on near-term profitability as the SaaS transition progresses.
(You can read the full research report on NetSol Technologies here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Seneca Foods Corp. (SENEA) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The Zacks Analyst Blog Highlights Walmart, Wells Fargo, Thermo Fisher Scientific, Seneca Foods and NetSol Technologies

Last Friday, the three most widely followed benchmark indexes closed a mixed week. The tech-heavy Nasdaq and the S&P 500 advanced 0.5% and 0.1%, respectively, while the Dow Jones Industrial Average receded 0.7%.
Investors weighed shifting expectations around U.S. monetary policy. Recent economic data reinforced the view that inflation is easing gradually, but uncertainty over the timing and pace of interest rate cuts limited broad risk-taking.
At the same time, strong corporate developments added fuel. Retail and tech companies delivered solid earnings and boosted sentiment further. Bond market volatility also played a role, with Treasury yields fluctuating in response to central bank commentary and global policy signals. The tech sector performed well.
Additionally, geopolitical developments and year-end positioning influenced sentiment. As the holiday period approached, lighter trading volumes amplified modest moves, leaving markets without a clear unified direction for the week.
Regardless of market conditions, we, here at Zacks, provide investors with unbiased guidance on how to beat the market.
As usual, Zacks Research guided investors over the past three months with its time-tested methodologies. Given the prevailing market uncertainty, you may want to look at our feats to prepare better for your next action.
Here are some of our key achievements:
Western Hamilton Insurance and Nu Holdings Surge Following Zacks Rank Upgrade
Shares of Hamilton Insurance Group, Ltd. HG have gained 20.1% (versus the S&P 500’s 2.9% increase) since it was upgraded to a Zacks Rank #1 (Strong Buy) on October 17.
Another stock, Nu Holdings Ltd. NU, which was upgraded to a #2 (Buy) also on October 17, has returned 10.9% since then.
A hypothetical portfolio of Zacks Rank # 1 (Strong Buy) stocks returned +14.3% in 2025 (through December 1st) vs. +14.9% for the S&P 500 index.
This portfolio returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index.
This hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index.
The Zacks Model Portfolio - consisting of Zacks Rank #1 stocks – has outperformed the S&P index by more than 12 percentage points since 1988 (through December 1st, 2025, the Zacks # 1 Rank stocks generated an annualized average return of +23.9% vs. +11.5% for the S&P 500 index).
Image Source: Zacks Investment Research
Zacks Recommendation Upgrades AerCap and Dycom
Shares of AerCap Holdings N.V. AER and Dycom Industries, Inc. DY have surged 18.7% (versus the S&P 500’s 2.3% rise) and 17.6% (versus the S&P 500’s 2.7% rise), respectively, since their Zacks Recommendation was upgraded to Outperform on October 16 and October 15.
While the Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon, the Zacks Recommendation aims to predict performance over the next 6 to 12 months. However, just like the Zacks Rank, the foundation for the Zacks Recommendation is trends in earnings estimate revisions.
The Zacks Recommendation classifies stocks into three groups — Outperform, Neutral and Underperform. While these recommendations are determined quantitatively, our analysts have the flexibility to override them for the 1100+ stocks they closely follow based on their better judgment of factors such as valuation, industry conditions and management effectiveness than the quantitative model.
To access our research reports with Zacks Recommendations for the 1100+ stocks we cover, click here>>>
Zacks Focus List Stocks Micron, Lam Research Shoot Up
Shares of Micron Technology, Inc. MU, which belongs to the Zacks Focus List, have gained 63.4% over the past 12 weeks. The stock was added to the Focus List on December 27, 2016. Another Focus-List holding, Lam Research Corporation LRCX, which was added to the portfolio on December 5, 2016, has returned 35.7% over the past 12 weeks. The S&P 500 has advanced 2.5% over this period.
The 50-stock Focus List portfolio returned +22% in 2025 (through November 30th, 2025) vs. +17.8% for the S&P 500 index and +10.9% for the equal-weight version of the index.
The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index. The portfolio had returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index. In 2022, the portfolio returned -15.2% vs. the S&P 500 index’s -17.96%.
Unlock all of our powerful research, tools and analysis, including the Focus List, Zacks #1 Rank List, Equity Research Reports, Zacks Earnings ESP Filter, Premium Screener and more, as part of Zacks Premium. Gain full access now >>
Zacks ECAP Stocks Thermo Fisher & Amgen Gain Significantly
Thermo Fisher Scientific Inc. TMO, a component of our Earnings Certain Admiral Portfolio (ECAP), has jumped 18.4% over the past 12 weeks. Amgen Inc. AMGN has also followed Thermo Fisher with 14.7% returns.
The Zacks Earnings Certain Admiral Portfolio (ECAP), which consists of 30 concentrated, ultra-defensive, long-term Buy-and-Hold stocks, returned -1.30% in the third quarter of 2025 vs. the S&P 500 index’s +8.1% gain (SPY ETF). In the year-to-date period through September 30th, the portfolio returned +2.72% vs. +14.84% gain for the S&P 500 index.
For the year 2024, the portfolio returned +16.26% vs. +24.89% for the S&P 500 index (SPY ETF).
In 2023, the portfolio returned +12.17% vs. +26.28% for the S&P 500 index. The portfolio returned -4.7% in 2022 vs. the S&P 500 index’s -17.96%.
With little to no turnover and annual rebalance periodicity, ECAP seeks to minimize capital loss by holding shares of companies whose earnings streams exhibit a proven 20+ year track record of surviving recessionary periods with minimal impact on aggregate earnings growth relative to the overall S&P 500.
The ECAP and many other model portfolios are available as part of Zacks Advisor Tools, a cloud-based solution to access Zacks award-winning stock, mutual fund and ETF research. Click here to schedule a demo.
Zacks ECDP Stocks Coca-Cola and Starbucks Outperform Peers
The Coca-Cola Company KO, which is part of our Earnings Certain Dividend Portfolio (ECDP), has returned 5.5% over the past 12 weeks. Another ECDP stock, Starbucks Corporation SBUX, has climbed 4.5% over the same time frame. Of course, the inclination of investors toward quality dividend stocks to secure an income stream amid heightened market volatility contributed to this performance.
Check Starbucks’ dividend history here>>>
With an extremely low beta and a history of minimum earnings variability over the last 20+ years, this 25-stock portfolio helps significantly mitigate risk.
The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -0.01% in 2025 Q3 vs. the S&P 500 index’s +8.1% gain and the Dividend Aristocrats ETF’s (NOBL) +2.90% return. Year-to-date (through September 30th), the portfolio returned +1.58% vs. +5.15% gain for the Dividend Aristocrat ETF.
For the full year 2024, the portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL.
The portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL. The portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL.
Click here to access this portfolio on Zacks Advisor Tools.
Zacks Top 10 Stock Credo Tech Delivers Solid Returns
Credo Technology Group Holding Ltd CRDO, from the Zacks Top 10 Stocks for 2025, has jumped 123.4% year to date compared with the S&P 500 Index’s 16.1% increase.
The Top 10 portfolio returned +25.4% this year (through the end of November 2025) vs. +17.8% for the S&P 500 index and +10.9% for the equal-weight version of the index.
The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index. The portfolio had returned +25.15% in 2023 vs. +26.28% for the S&P 500 index.
Since 2012, the Top 10 portfolio has produced a cumulative return of +2,530.8% through the end of November 2025 vs. +562% for the S&P 500 index and +401% for the equal-weight version of the index. The portfolio has produced an average return of +26.1% in the period 2012 through November 30, 2025, vs. +13.2% for the S&P 500 index and +10.5% for the equal-weight version of the index.
Zacks Naming Top 10 Stocks for 2026
Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Beat the Market the Zacks Way: Micron, Credo, Coca Cola in Focus

Thermo Fisher Scientific Inc. TMO recently announced the enrollment of the first patient in its new PPD CorEvitas Alzheimer’s Disease Registry. The registry is designed as an international, multi-country initiative that will generate robust, harmonized, fit-for-purpose real-world data under a common global protocol. It will further support novel evaluations of drug safety and effectiveness that are critical for regulator, clinician, patient and caregiver communities.
TMO Stock Outlook Following the News
After the announcement, TMO shares dipped slightly 0.03% last Thursday.
On a positive note, the CorEvitas Alzheimer’s Disease Registry expands the growing portfolio of Thermo Fisher’s PPD CorEvitas Clinical Registries — proprietary disease registries that contain robust, structured clinician and patient-reported data from more than 500 investigator sites, with longitudinal data collected on over 100,000 patients. Hence, the news should favorably support TMO stock’s upward momentum.
Thermo Fisher has a market capitalization of $213.34 billion. The company’s earnings yield of 3.9% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.9%.
About TMO’s PPD CorEvitas Alzheimer’s Disease Registry
The registry has a longitudinal design, coupled with clinician-reported data from routine practice, which will generate a comprehensive understanding of Alzheimer’s therapy outcomes in real-world settings. The registry is expected to generate insights into long-term safety and treatment patterns, track the evolving use of approved therapies, identify unmet medical needs, clarify the disease’s impact on patients, and evaluate clinical outcomes associated with current treatment options.
Detailed monitoring and assessment of drug safety events are integral to the registry. This includes MRI-based evaluations of brain bleeding and swelling that may occur with certain treatments, as well as measures of plaque clearance — an important indicator of treatment effectiveness and its correlation with cognitive outcomes. This data will help generate a more complete understanding of safety and clinical outcomes in this patient population.
Industry Prospects Favor TMO
Alzheimer’s disease is a progressive neurodegenerative disorder that gradually damages brain cells, impairing memory, language, decision-making abilities and ultimately, the ability to perform daily tasks. Per a report published in PubMed Central, an estimated 7.2 million Americans aged 65 and older are living with Alzheimer.
Image Source: Zacks Investment Research
As a leading cause of death in the United States, the disease represents a significant public health challenge and underscores the need for rigorous evidence to guide therapeutic development and patient care (according to CDC report). Although there is currently no way to prevent or cure Alzheimer’s, treatments may help manage symptoms and potentially slow decline.
Another Development by TMO
Thermo Fisher recently announced the expansion of its Gibco Bacto CD portfolio. The Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X) are two next-generation chemically defined formulations to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).
TMO Stock Price Performance
In the past year, TMO shares have risen 8.1% compared with the industry’s 1.2% growth.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are BrightSpring Health Services BTSG, Illumina ILMN and Insulet PODD. While BrightSpring and Illumina sport a Zacks Rank #1 (Strong Buy) each, Insulet carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for BrightSpring Health Services’ 2025 EPS have increased 5.7% in the past 30 days. Shares of the company have surged 94.8% in the past year compared with the industry’s 6.7% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%.
Illumina shares have lost 5.7% over the past year. Estimates for the company’s 2025 EPS have jumped 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.
Insulet shares have risen 10.7% over the past year. Estimates for the company’s 2025 EPS have increased 6.5% to $4.89 in the past 60 days. PODD’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 17.8%. In the last reported quarter, it posted an earnings surprise of 9.7%.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include
Stock #1: A Disruptive Force with Notable Growth and Resilience
Stock #2: Bullish Signs Signaling to Buy the Dip
Stock #3: One of the Most Compelling Investments in the Market
Stock #4: Leader In a Red-Hot Industry Poised for Growth
Stock #5: Modern Omni-Channel Platform Coiled to Spring
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.
Download Atomic Opportunity: Nuclear Energy's Comeback free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch

Friday, December 19, 2025
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Wells Fargo & Co. (WFC) and Thermo Fisher Scientific Inc. (TMO), as well as two micro-cap stocks Seneca Foods Corp. (SENEA) and NetSol Technologies, Inc. (NTWK). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> Are the Markets Setting Up for a Santa Claus Rally?
Today's Featured Research Reports
Walmart’s shares have outperformed the Zacks Retail - Supermarkets industry over the past six months (+21.3% vs. +19.9%). The company’s performance reflects strong execution across its omnichannel model, with robust store-led fulfillment, solid e-commerce growth and sustained market share gains.
Third-quarter fiscal 2026 results highlight robust comparable sales, broad-based traffic growth and rapidly expanding higher-margin businesses such as advertising and membership, which represent a meaningful share of operating income. Faster delivery speeds, improved inventory availability and marketplace expansion continue to support e-commerce growth. Management’s raised fiscal 2026 view underscores confidence in sustaining growth.
However, margin expansion remains constrained by elevated operating costs and tariff risks. Currency volatility, intense competition and an ongoing mix shift toward lower-margin essentials amid macroeconomic uncertainty are also concerns.
(You can read the full research report on Walmart here >>>)
Shares of Wells Fargo have outperformed the Zacks Financial - Investment Bank industry over the past six months (+23.7% vs. +22.3%). The company’s earnings surpassed the estimates in each of the trailing four quarters. The Federal Reserve's June 2025 removal of the $1.95 trillion asset cap allows growth in deposits, loans, and fee-based services.
The bank also gains room to scale fee-based businesses like payment services and asset management, enhancing its revenue mix. After clearing the 2025 Fed stress test, Wells Fargo raised its dividend, backed by strong liquidity and capital position. Also, strategic investments in talent and technology support long-term growth.
Yet, despite the recent Fed rate cuts, NII recovery may remain slow, pressuring near-term revenue growth. The mortgage banking income remains weak amid ongoing mortgage rate volatility. Also, rising expense base may weigh on its profitability.
(You can read the full research report on Wells Fargo here >>>)
Thermo Fisher Scientific’s shares have outperformed the Zacks Medical - Instruments industry over the past six months (+43.5% vs. +16.9%). The company continues to strengthen its foundation by consistently advancing its growth strategy. The company’s latest round of innovations supports scientific breakthroughs, advances precision medicine and greater lab productivity for customers.
Thermo Fisher is embedding OpenAI’s capabilities into its products and services to make an even bigger impact for customers and enhance productivity. Strategic acquisitions, such as the newly added Solventum’s Purification and Filtration Business, further enhance its offerings.
The Zacks’ model forecasts a 5.1% CAGR growth in the company’s revenues through 2025-2027. Meanwhile, a highly leveraged balance sheet poses liquidity concerns. Shifting U.S. policies have weighed on the academic and government end-market clients, affecting its sales. Currency woes add to the worry.
(You can read the full research report on Thermo Fisher Scientific here >>>)
Shares of Seneca Foods have outperformed the Zacks Food - Miscellaneous industry over the past six months (+26.2% vs. -7.8%). This microcap company with market capitalization of $771.74 million benefits from resilient global demand for affordable, shelf-stable foods, with first-half fiscal 2026 sales up 3.7% and strong volume growth led by canned and frozen vegetables, which remain more than 82.5% of sales.
Improved harvest yields, pack efficiency and structural cost controls are supporting margin normalization, as high-cost inventory rolls off. Deleveraging, lower interest expense and ample liquidity have strengthened the balance sheet, while the Green Giant shelf-stable acquisition enhances branded scale and mix.
Yet, margin gains are heavily influenced by LIFO credits, masking underlying FIFO cost pressure and earnings volatility. Elevated inventories increase working-capital risk and variable-rate debt maintains sensitivity to rates. Valuation is compelling, offering upside if normalized margins and cash flow durability are sustained.
(You can read the full research report on Seneca Foods here >>>)
NetSol Technologies’ shares have outperformed the Zacks Computer - Software industry over the past six months (+7.1% vs. -2.1%). This microcap company with market capitalization of $36.57 million operates in a large, underpenetrated global asset finance and leasing software market undergoing ongoing digital transformation. Its AI-enabled, modular Transcend Platform is seeing growing adoption among OEMs, captives, and financial institutions.
NetSol Technologies’ transition to a SaaS and cloud-first model is improving predictability. Investments in AI, including Check AI and Transcend AI Labs, enhance product differentiation and scalability, while partnerships across China and Southeast Asia reinforce regional positioning.
Balancing the opportunity are ongoing risks, including the structural decline of high-margin license revenue, margin pressure from rising SG&A and FX volatility, and earnings sensitivity to currency movements. High customer concentration, uneven services growth, and working capital pressure continue to weigh on near-term profitability as the SaaS transition progresses.
(You can read the full research report on NetSol Technologies here >>>)
Other noteworthy reports we are featuring today include McDonald's Corporation (MCD), Uber Technologies, Inc. (UBER) and Infosys Limited (INFY).
Director of Research
Sheraz Mian
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
Today's Must Read
Featured Reports
McDonald's (MCD) Gains from Expansion Amid Margin Pressure
Per the Zacks analyst, McDonald's is benefiting from strong international sales, marketing execution, and loyalty growth, while weaker traffic from lower-income consumers remains a headwind.
Uber (UBER) Benefits From Delivery Business Amid High Debt
The Zacks Analyst likes Uber's efforts to expand its Delivery operations in response to the surge in business. However, high debt does not bode well for its bottom line.
Digital Transformation, AI Proliferation Aid Infosys (INFY)
Per the Zacks analyst, Infosys is benefiting from large deal wins and higher investments by clients in digital transformation, artificial intelligence and automation.
Investments Aid Sempra Energy (SRE) Amid Poor Solvency
Per the Zacks analyst, Sempra Energy makes systematic investments to maintain and upgrade the reliability of its infrastructure. Yet its poor financial ratios indicate weak solvency position.
CDW Benefits From Strong Market Demand Amid Macro Headwinds
Per the Zacks analyst, improvements in customer spending across various market segments is driving CDW's top-line performance. Macroeconomic volatility in the international market remains concerns.
Growing Top Line, Solid Capital Position Aid Palomar (PLMR)
Per the Zacks analyst, Palomar's growing revenues, driven by higher premiums and net investment income have led to significant growth. Moreover, robust capital position supports capital deployment.
Crysvita and Dojolvi Sales Drive Ultragenyx (RARE), Setbacks a Woe
Per the Zacks Analyst, Ultragenyx's marketed products have been witnessing strong growth year-over-year. However, any pipeline/regulatory setback will hinder the stock's growth potential.
New Upgrades
Canadian (CNQ) to Gain from Completion of AOSP Swap With Shell
The Zacks analyst believes that Canadian Natural's 100% ownership of the Athabasca Oil Sands Project (AOSP) will add about 31,000 bbl/d of zero-decline bitumen, boosting long-term cash flow.
Phillips 66's (PSX) Diversified Business Model Aids Growth
Per the Zacks analyst, Phillips 66's focus on multiple sectors, like refining and midstream, generates stable cash flows. Further, its EPIC NGL acquisition expands its footprint in the NGL sector.
Afirma Solution's Outperformance Aid Veracyte (VCYT)
The Zacks Analyst is impressed with Veracyte's comprehensive Afirma solution, which demonstrated strong 13% volume growth in the third quarter of 2025 driven by growing number of new customers.
New Downgrades
Venture Global (VG) Arbitration Clouds Cash Flow and SPAs
Per the Zacks analyst, Venture Global faces mounting arbitration risks after a breach ruling tied to Calcasieu Pass, with potential multi-billion-dollar claims threatening cash flow stability.
Merger-Related Costs, Low Box Volumes Ail Smurfit Westrock (SW)
Per the Zacks Analyst, merger-related costs and cost inflation continue to weigh on Smurfit Westrock. Lower box volumes are also challenging.
Archer Daniels (ADM) Witnesses Soft Ag Services and Oilseeds Unit
Per the Zacks analyst, Archer Daniels' Ag Services and Oilseeds unit struggled in third-quarter 2025 on weak crush margins and global trade volumes. Logistical challenges and product mix also hurt.
Zacks' Research Chief Picks Stock Most Likely to "At Least Double"
Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.
See Our Top Stock to Double (Plus 4 Runners Up) >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Stock Reports for Walmart, Wells Fargo & Thermo Fisher Scientific

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro S&P 500 (Symbol: UPRO) where we have detected an approximate $208.8 million dollar outflow -- that's a 4.4% decrease week over week (from 42,200,000 to 40,350,000). Among the largest underlying components of UPRO, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.7%, Walt Disney Co. (Symbol: DIS) is up about 0.8%, and Booking Holdings Inc (Symbol: BKNG) is higher by about 0.8%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $45.88 per share, with $122.1899 as the 52 week high point — that compares with a last trade of $114.95. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Top Ten Hedge Funds Holding SNSS
Institutional Holders of CAPS
TPNL Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Outflows: UPRO, TMO, DIS, BKNG

Thermo Fisher Scientific TMO recently announced the expansion of its Gibco Bacto CD portfolio. The Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X) are two next-generation chemically defined formulations to enhance and simplify plasmid DNA and recombinant protein production using Escherichia coli (E. coli).
The latest development represents a major advancement in microbial bioprocessing technology and is expected to bolster the company’s Cell Culture and Cell Therapy business.
TMO Stock Outlook Following the News
After the announcement yesterday, TMO shares rose 0.7%, closing the session at $575.91. The Bacto CD Supreme platform is built on decades of Thermo Fisher’s Gibco media innovation and quality heritage and extends the proven expertise in mammalian systems into microbial bioprocessing. Hence, the news should favorably support TMO stock’s upward momentum.
Thermo Fisher has a market capitalization of $215.01 billion. The company’s earnings yield of 3.9% is well ahead of the industry’s -3.5% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.9%.
More on Thermo Fisher’s Latest Launch
As demand for plasmid DNA continues to surge to support expanding gene therapy and mRNA vaccine pipelines, scalable microbial production platforms have become mission-critical. Biomanufacturers developing these therapies face growing pressure to increase yields while maintaining consistency at scale. The new Gibco Bacto CD Supreme FPM Plus and Feed (2X) address these needs by simplifying E. coli bioprocessing workflows and delivering predictable, high-quality results.
The Bacto CD Supreme FPM Plus medium provides a hydrolysate-free, chemically defined composition that supports high-density E. coli cultures in both batch and fed-batch processes. Designed to work across a broad range of strains, including Thi-1 mutants and auxotrophic variants, it helps streamline process development while maintaining robust and reproducible growth performance.
Image Source: Zacks Investment Research
When paired with Bacto CD Supreme Feed (2X), customers can extend culture performance and achieve up to 120% higher plasmid DNA production yield compared to terrific broth with other lab-prepared feeds. Together, these formulations enable consistent, high-performance results from lab to commercial scale while removing the variability and compliance risk associated with animal-derived components. Early adopters of the platform are said to have reported measurable impact during prototype testing.
Industry Prospects Favoring TMO
Per a Grand View Research report, the global plasmid DNA manufacturing market was valued at $2.13 billion in 2024 and is expected to grow at a CAGR of 21.4% through 2030. With the rising demand for robust disease treatment therapies, several companies and research organizations are accelerating R&D efforts for advanced therapies that target the cause of disease at a genomic level, resulting in increased demand for plasmid DNA.
More Updates From Thermo Fisher
This month, Thermo Fisher announced an expansion of its bioprocessing capabilities across Asia to support the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India. It has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, strengthening a strategic regional network designed to enhance speed, efficiency and sustainability in biomanufacturing.
TMO Stock Price Performance
In the past three months, TMO shares have risen 21.8% compared with the industry’s 7.5% growth.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are BrightSpring Health Services BTSG, Illumina ILMN and Insulet PODD. While BrightSpring and Illumina eachsport a Zacks Rank #1 (Strong Buy), Insulet carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for BrightSpring Health Services’ 2025EPS have increased 5.7% in the past 30 days. Shares of the company have surged 94.8% in the past year compared with the industry’s 6.7% growth. BTSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.1%. In the last reported quarter, it delivered an earnings surprise of 11.1%.
Illumina shares have fallen 5.7% in the past year. Estimates for the company’s 2025 EPS have jumped 0.9% to $4.71 in the past 30 days. ILMN’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 6.7%. In the last reported quarter, it posted an earnings surprise of 15.5%.
Insulet shares have risen 10.7% in the past year. Estimates for the company’s 2025 EPS have increased 6.5% to $4.89 in the past 60 days. PODD’s earnings topped estimates in each of the trailing four quarters, delivering an average surprise of 17.8%. In the last reported quarter, it posted an earnings surprise of 9.7%.
Zacks Naming Top 10 Stocks for 2026
Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.
From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio

Fintel reports that on December 11, 2025, Citigroup upgraded their outlook for Thermo Fisher Scientific (NYSE:TMO) from Neutral to Buy.
Analyst Price Forecast Suggests 9.04% Upside
As of December 6, 2025, the average one-year price target for Thermo Fisher Scientific is $631.27/share. The forecasts range from a low of $538.49 to a high of $708.75. The average price target represents an increase of 9.04% from its latest reported closing price of $578.91 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Thermo Fisher Scientific is 48,792MM, an increase of 11.56%. The projected annual non-GAAP EPS is 28.08.
What is the Fund Sentiment?
There are 3,708 funds or institutions reporting positions in Thermo Fisher Scientific. This is an decrease of 48 owner(s) or 1.28% in the last quarter. Average portfolio weight of all funds dedicated to TMO is 0.52%, an increase of 3.72%. Total shares owned by institutions decreased in the last three months by 1.81% to 380,491K shares. The put/call ratio of TMO is 1.27, indicating a bearish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,136K shares representing 3.23% ownership of the company. In its prior filing, the firm reported owning 11,913K shares , representing an increase of 1.84%. The firm decreased its portfolio allocation in TMO by 25.94% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 10,716K shares representing 2.85% ownership of the company. In its prior filing, the firm reported owning 10,627K shares , representing an increase of 0.82%. The firm decreased its portfolio allocation in TMO by 27.01% over the last quarter.
Capital World Investors holds 10,285K shares representing 2.74% ownership of the company. In its prior filing, the firm reported owning 9,579K shares , representing an increase of 6.87%. The firm increased its portfolio allocation in TMO by 20.70% over the last quarter.
Geode Capital Management holds 8,170K shares representing 2.17% ownership of the company. In its prior filing, the firm reported owning 8,115K shares , representing an increase of 0.68%. The firm increased its portfolio allocation in TMO by 9.62% over the last quarter.
Jpmorgan Chase holds 7,273K shares representing 1.94% ownership of the company. In its prior filing, the firm reported owning 9,154K shares , representing a decrease of 25.86%. The firm decreased its portfolio allocation in TMO by 90.80% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Citigroup Upgrades Thermo Fisher Scientific (TMO)

Looking at the universe of stocks we cover at Dividend Channel, on 12/15/25, DT Midstream Inc (Symbol: DTM), HCA Healthcare Inc (Symbol: HCA), and Thermo Fisher Scientific Inc (Symbol: TMO) will all trade ex-dividend for their respective upcoming dividends. DT Midstream Inc will pay its quarterly dividend of $0.82 on 1/15/26, HCA Healthcare Inc will pay its quarterly dividend of $0.72 on 12/29/25, and Thermo Fisher Scientific Inc will pay its quarterly dividend of $0.43 on 1/15/26. As a percentage of DTM's recent stock price of $117.75, this dividend works out to approximately 0.70%, so look for shares of DT Midstream Inc to trade 0.70% lower — all else being equal — when DTM shares open for trading on 12/15/25. Similarly, investors should look for HCA to open 0.15% lower in price and for TMO to open 0.07% lower, all else being equal.
Below are dividend history charts for DTM, HCA, and TMO, showing historical dividends prior to the most recent ones declared.
DT Midstream Inc (Symbol: DTM):
HCA Healthcare Inc (Symbol: HCA):
Thermo Fisher Scientific Inc (Symbol: TMO):
In general, dividends are not always predictable, following the ups and downs of company profits over time. Therefore, a good first due diligence step in forming an expectation of annual yield going forward, is looking at the history above, for a sense of stability over time. This can help in judging whether the most recent dividends from these companies are likely to continue. If they do continue, the current estimated yields on annualized basis would be 2.79% for DT Midstream Inc, 0.61% for HCA Healthcare Inc, and 0.30% for Thermo Fisher Scientific Inc.
In Thursday trading, DT Midstream Inc shares are currently off about 1.3%, HCA Healthcare Inc shares are down about 4%, and Thermo Fisher Scientific Inc shares are up about 1.9% on the day.
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »
Also see:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Ex-Dividend Reminder: DT Midstream, HCA Healthcare and Thermo Fisher Scientific

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $563.7 million dollar outflow -- that's a 0.7% decrease week over week (from 538,750,000 to 535,000,000). Among the largest underlying components of ITOT, in trading today Tesla Inc (Symbol: TSLA) is off about 1.6%, Palantir Technologies Inc (Symbol: PLTR) is down about 2.1%, and Thermo Fisher Scientific Inc (Symbol: TMO) is up by about 0.4%. For a complete list of holdings, visit the ITOT Holdings page » The chart below shows the one year price performance of ITOT, versus its 200 day moving average:
Looking at the chart above, ITOT's low point in its 52 week range is $105 per share, with $150.70 as the 52 week high point — that compares with a last trade of $150.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Free Report: Top 8%+ Dividends (paid monthly)
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Also see:
Top Ten Hedge Funds Holding LUNR
Institutional Holders of FAT
Funds Holding AND
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy ETF Outflows: ITOT, TSLA, PLTR, TMO

Fintel reports that on December 9, 2025, Goldman Sachs initiated coverage of Thermo Fisher Scientific (NYSE:TMO) with a Buy recommendation.
Analyst Price Forecast Suggests 11.10% Upside
As of December 6, 2025, the average one-year price target for Thermo Fisher Scientific is $631.27/share. The forecasts range from a low of $538.49 to a high of $708.75. The average price target represents an increase of 11.10% from its latest reported closing price of $568.21 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Thermo Fisher Scientific is 48,792MM, an increase of 11.56%. The projected annual non-GAAP EPS is 28.08.
What is the Fund Sentiment?
There are 3,709 funds or institutions reporting positions in Thermo Fisher Scientific. This is an decrease of 43 owner(s) or 1.15% in the last quarter. Average portfolio weight of all funds dedicated to TMO is 0.52%, an increase of 3.84%. Total shares owned by institutions decreased in the last three months by 1.80% to 380,491K shares. The put/call ratio of TMO is 1.24, indicating a bearish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 12,136K shares representing 3.23% ownership of the company. In its prior filing, the firm reported owning 11,913K shares , representing an increase of 1.84%. The firm decreased its portfolio allocation in TMO by 25.94% over the last quarter.
VFINX - Vanguard 500 Index Fund Investor Shares holds 10,716K shares representing 2.85% ownership of the company. In its prior filing, the firm reported owning 10,627K shares , representing an increase of 0.82%. The firm decreased its portfolio allocation in TMO by 27.01% over the last quarter.
Capital World Investors holds 10,285K shares representing 2.74% ownership of the company. In its prior filing, the firm reported owning 9,579K shares , representing an increase of 6.87%. The firm increased its portfolio allocation in TMO by 20.70% over the last quarter.
Geode Capital Management holds 8,170K shares representing 2.17% ownership of the company. In its prior filing, the firm reported owning 8,115K shares , representing an increase of 0.68%. The firm increased its portfolio allocation in TMO by 9.62% over the last quarter.
Jpmorgan Chase holds 7,273K shares representing 1.94% ownership of the company. In its prior filing, the firm reported owning 9,154K shares , representing a decrease of 25.86%. The firm decreased its portfolio allocation in TMO by 90.80% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	32.94 21.19
Price/Sales	4.32 3.02
P/B	3.66 2.24
P/FCF	35.22 18.80

Indicator	TTM Median
ROE	13.28 24.85
ROA	6.62 6.38
ROI	8.15 9.94
Net Worth	185.03 0.21
Quick Ratio	1.50 1.71
Current Ratio	1.93 2.80

Indicator	TTM Median
Net Profit Margin	15.23 11.05
Operating Margin	17.14 14.24
Gross Margin	41.18 68.98
Return on tangible equity	0.00 52.87

Indicator	TTM Median
EPS	5.79 0.37
EPS Forecast	5.50 0.37
Revenue	10.86B 17.00M
Gross Profit	4.41B —
EBITDA	2.52B —

Thermo Fisher Scientific Inc

TTM metrics for the latest quarter under IFRS and their historical dynamics

Valuation

Debts

Efficiency

Other ratios

Revenue